🇺🇸 FDA
Pipeline program

Arvisol placebo, Arvisol 150mg

APHP180619

Phase 2 small_molecule active

Quick answer

Arvisol placebo, Arvisol 150mg for Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials